Overexpression of p95HER2 in breast cancer is associated with poor prognosis
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
HER2 overexpression is found in 25–30% of breast cancers and has been associated with increased risk of relapse and mortality. Studies have indicated that metastatic nodal tissue contains higher levels of p95HER2, a truncated fragment of HER2, than does primary nodal tissue. Sáez et al. have investigated whether p95HER2 can be used as a prognostic indicator in breast cancer.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.